22EL-758 On-Demand eCast: Prevention and Management of Infusion Reactions

Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)

Live Program Date: Wednesday, July 27, 2022
Program Number: 22EL-758

Educational Track: Technical/Clinical
Topic: Cellular Therapy
Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Intermediate

Faculty
(titles and affiliations at the time of the live program)
Director/Moderator: Thomas R. Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
Speakers: Kevin Land, MD, Vice President Clinical Services, Vitalant, San Antonio, TX; Thomas R. Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA

Program Description
Reactions to cellular infusions are increasingly common, given the rapidly expanding arsenal of cellular products that are available to treat cancer and other diseases. This program will discuss the range of those reactions, spanning the spectrum from the consequences of infusing ABO incompatible progenitor cell products to reactions from components of the product preparation. Strategies for minimizing those reactions and treating them if they occur will be reviewed. Optimal reporting practices and grading of infusion reactions will also be discussed.

Learning Objectives
After participating in this educational activity, participants should be able to:

  • Identify the causes of cellular infusion reactions.
  • Describe the spectrum of reactions to cellular infusions.
  • Discuss management strategies for infusion reactions.
  • Review optimal reporting practices for infusion reactions.

How to Claim Continuing Education Credit

  • Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.
  • Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.

Director, Moderator & Speaker

Speaker Image for Thomas Spitzer
Massachusetts General Hospital & Harvard Medical School

Speaker

Speaker Image for Kevin Land
Vitalant

Related Products

Thumbnail for AM23-ST-07-O: Standardization of Post-Thaw Viability Testing Method for Cryopreserved Hematopoietic Progenitor Cells (Enduring)
AM23-ST-07-O: Standardization of Post-Thaw Viability Testing Method for Cryopreserved Hematopoietic Progenitor Cells (Enduring)
Cryopreservation preserves hematopoietic progenitor cells (HPC) for future use, but the freezing and thawing processes can impact viability. To ensure sufficient viable cells for downstream applications, post-thaw viability testing is essential…
Thumbnail for AM24-SN-09-O: Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century (Enduring)
AM24-SN-09-O: Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century (Enduring)
37 cell and gene therapy (CGT) products licensed in the US with a steady pipeline of anticipated approvals moving forward. Each one of these has a unique contracting and onboarding process…
Thumbnail for AM23-MN-22-O: Cellular Starting Material (CSM) Forum (Enduring)
AM23-MN-22-O: Cellular Starting Material (CSM) Forum (Enduring)
The AABB Cellular Starting Material (CSM) Forum connects diverse organizations involved in Cellular Starting Material (CSM) for biotherapies. CSM is used for a variety of novel biotherapies including cellular therapy, gene and cell therapy, and regenerative medicines…
Thumbnail for AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
The Biotherapies Spotlight Session will cover several diverse topics. The use of controlled incremental filtration microfluidics rather than monoclonal antibody selection systems to isolate B-cells from whole blood will be discussed…